Last reviewed · How we verify
CVL006 in combination with SKB264 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CVL006 in combination with SKB264 (CVL006 in combination with SKB264) — Convalife (Shanghai) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CVL006 in combination with SKB264 TARGET | CVL006 in combination with SKB264 | Convalife (Shanghai) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CVL006 in combination with SKB264 CI watch — RSS
- CVL006 in combination with SKB264 CI watch — Atom
- CVL006 in combination with SKB264 CI watch — JSON
- CVL006 in combination with SKB264 alone — RSS
Cite this brief
Drug Landscape (2026). CVL006 in combination with SKB264 — Competitive Intelligence Brief. https://druglandscape.com/ci/cvl006-in-combination-with-skb264. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab